Introduction
Two pyrimidine nucleoside phosphorylases are present in the cytosol of mammalian cells, i.e. thymidine [E C 2.4.2.4.J and uridine [E C 2.4.2.3.] (Krenitsky et al., 1964) . These two enzymes play an im portant role in nucleoside degradation, as well as in the process of recovery (salvage) of py rimidine (Granharov et al, 1991) . Inhibitors of these enzymes were applied in chem otherapy by decreasing the in vivo degradation of pyrimidine nucleosides analogues exhibiting antitum or activ ity (M ukherjee et al, 1963 (M ukherjee et al, , Niedzwicki et al, 1981 . A num ber of inhibitors of uridine phosphorylase (UrdPase) activity are known which are, among others, 5-substituted uracil derivatives (Baker et al, 1970 , Niedzwicki et al, 1983 . Little is known, however, of thymidine phosphorylase (dThdPase) inhibitors, and there fore, we have decided to study uracil derivatives as inhibitors of dThdPase isolated from human uteri and uterine leiomyomas.
Materials and Methods
The investigated m aterial were four leiomyomas and uteri operated in women aged 30-45 years. Histopathological results revealed the endom et rium to be in the proliferative stage. Directly after surgery the tissues were deep-frozen (-7 0 °C) and then taken for analysis.
Chemicals
5-FU, 6-AU, 4,6-DHNiP, 6-BTU, dThd, T, U were obtained from Sigma Chemical Company St.Louis, MO, USA; 5-BrU, 5-NiU from Fluka AG Loba Chemie (Wien). AMU, AMT, AMFU, AMC, were obtained by Ozierov (Ozierov et al, 1991) , Th5 by Dramiriski (Rutkowski and Dramiriski, 1991) . D EA E-Sepharose was obtained from Phar macia Fine Chemicals. All other chemicals were of reagent or analytical grade and were used without further purification.
Enzym e preparation
dThdPase was partially purified according to the method described by Yoshimura et al. (1990) for human placentas with our own modifications. The 0939-5075/97/0900-0670 $ 06.00 © 1997 Verlag der Zeitschrift für Naturforschung. All rights reserved. D tissues were homogenized in 4 volumes of ice cold buffer A [(1 m M EDTA, 0.02% 2-mercaptoethanol, 2 m M phenylmethanesulfonyl fluoride (PMSF), 20 mM sodium phosphate buffer, pH 7.5)] and centrifuged at 50000 x g for lh.
The supernatant was mixed overnight with 40% saturation of ammonium sulfate at 4 °C, then the precipitate was dissolved in buffer A, dialyzed against this buffer and next dialyzed against buffer B (1 m M EDTA, 0.02% 2-m ercaptoethanol, 10 m M tris(hydroxymethyl)aminomethane-maleate, pH 6.5). The dialysed solution was applied to a DEAE-Sepharose (Pharmacia) column and eluted with a linear gradient of NaCl (50-250 m M ). Then the active fractions were pooled and stored at -7 0 °C, or were taken for analysis. dThdPase from human uterine leiomyomas and uteri was purified 40-fold and 10-fold, respectively.
Enzym e assays
dThdPase activity was assayed by the spectrophotom etric method described by Yoshimura et al. (1990) in our own modification, using the trans formation of thymine from thymidine in the pres ence of arsenate. The incubation mixture of 0.5 ml final volume contained 0.1 m Tris-arsenate buffer (pH 6.5), 10 m M dThd and crude or partially puri fied enzyme. After 1 h incubation at 37 °C, the reaction was stopped by adding 0.5 ml 1 n NaO H and the thymine formed was m easured with absor bance at 300 nm. The inhibition studies were per formed in the same conditions, but the incubation mixture of 0.5 ml final volume contained an ap propriate concentration of inhibitor and substrate. The protein content was determ ined according to the method described by Bradford (1976) .
One unit of activity of dThdPase was defined as the amount of the enzyme which was required to form 1 jiM of free base per 1 h. Specific activity was defined as the number of the enzyme activity units per milligram of protein. K m values were cal culated from eight substrate concentrations using equations described by Michal (1974) . K ; values were calculated according to the same m ethod af ter the kind of inhibition had been determ ined using Dixon plot (Michal G. 1974) .
Results and Discussion
The 5-FU derivatives, i.e. 5-FUR, 5-FUdR and 5-D FU R are converted to 5-FU by pyrimidine nu cleoside phosphorylases. One of them is dThdPase specific for pyrimidine 2'deoxy-nucleosides, mainly dThd which may be responsible for the de gradation of FU dR to 5-FU, primarily in human tumors. The other -UrdPase specific mainly for Urd is responsible for degradation of FUR, and also FU dR in m urine tumors (Razzel et al., 1967; Kono et al., 1983; Miwa et al., 1986) . Degradation of the drugs by phosphorylases is the limiting factor of their antitum or activity and, therefore, it appeared pertinent to find inhibitors of these enzymes. In fact, the application of FUR together with 2,2'-anhydro-5-ethyluridine (A N EU R ), which is a potent inhibitor of UrdPase, markedly enhanced the antitum or activity of FU R and FU dR (Veres et al., 1985 and 1987) . A N EU R is not inhibitory for dThdPase and, hence, it should not interfere with the conversion of D FU R to 5-FU by dThdPase in human tumors (Kono et al., 1983) . Strong inhibitors of dThdPase, however, are 6-anilino-and 6-(l-naphthylmethylamino-) deriva tives of uracil, which were investigated in E.coli (Baker et al., 1970) . On the other hand, they did not inhibit or inhibited insignificantly (less than 10%) the effect of dThdPase on FU dR in five dif ferent mammalian preparations . There are, therefore, differences between chemical and steric properties of dThdPases from eukaryotes and prokaryotes. The investigations on the enzyme have been mainly carried out with ani mal material. A detailed study of kinetics for dThdPase isolated from mouse liver revealed to be consistent with Michaelis-Menten kinetics (Iltzch et al., 1985) . The importance of using hu man phosphorylases to evaluate potential inhibi tors of these enzymes for clinical use should be emphasised. D aker et al. (1990) reported that dThdPase from intact blood cells follows the Michaelis-M enten kinetics with K m = 0.1-0.19 m M . In our research dThdPase isolated from uteri and uterine leiomyomas, and partially purified (frac tionation to saturation with ammonium sulfate, chrom atography on DEAE-Sepharose) also re vealed the hyperbolic kinetics with K m = 0.2 mM for uterine leiomyomas and 0.25 m M for the uteri. This enzyme was subject to the effect of com pounds deriving from uracil. They were 5-BrU, 5-NiU, 5-FU, 6-BTU, 4,6-DHNiP, 6-AU, U, AMU, AMFU, AMC, T 5 and AMT. These results re vealed a few inhibitors of this enzyme (Table I) . Table I . Effect of pyrimidine derivatives on partially purified dThdPase activity from human uterine leiomyomas and uteri (see Materials and Methods). The compounds (0.1 m M ) were tested using dThd as substrate (0.2 mM). 1 unit of enzyme activity (U) is defined as the quantity that catalyzes the formation of 1.0 jamol of free thymine per hour. Specific activity of dThdPase is expressed as U/mg of protein.
Each value: the mean ± SD for four experiments, NS-mean non significant (i.e. p>0.05), p-values were calculated using Student's t -test, comp., uncomp, or m.inh. indicates competitive,uncompetitive or mixed inhibition. dThdPase from human uterine leiomyomas and uteri was purified 40-fold and 10-fold, respectively. U, uracil: 6-AU, 6-aminouracil; 5-FU, 5-fluorouracil; 5-NiU, 5-nitrouracil; 5-BrU, 5-bromouracil; 4,6-DHNiP, 4,6-dihydroxy-5nitropyrimidine; 6-BTU, 6-benzyl-2-thiouracil; AMT, allyloxymethylthymine; AMU, allyloxymethyluracil; AMFU, allyloxymethyl-5-fluorouracil; Th 5, l [ ( l ',3-dihydroxy)-2,2 (propoxymethyl)]thymine; AMC, allyloxymethylcytosine.
Desgranges has also reported, that the activity of dThdPase from blood platelets is inhibited com petitively by various C-5 or C-6 substitutions of uracil (Desgranges et al., 1982) . In our study 5-BrU appeared to be the most po tent and competitive inhibitor for dThdPase iso lated from both uteri and from uterine leiomyo mas with K x = 6.1 [iM and 1.06 [am, respectively (Table I, Figs 1, 2) . This result has not revealed a significant difference in sensitivity of dThdPase isolated from a benign tum or (uterine leiomyoma) and from adjacent tissue (uterus) to 5-BrU, but pointed to a different sensitivity of dThdPase iso lated from these human tissues in comparison with this enzyme isolated from other mammalian tis sues. The inhibition studies with mouse liver dThdPase did not reveal an inhibition at the maxi mum 5-BrU concentration of 2 mM (G ranharov et al., 1991). 5-BrU, however, studied in intact plate lets was one of the most active inhibitors with K, of 28 [im next to 6-amino-5-bromouracil and 6-aminothymine with a of 6 and 11 (im, respec tively (Desgranges et al., 1982) .
5-NiU, on the other hand, appeared to be an equally effective inhibitor for dThdPase as 5-BrU in tissues studied by us (Table I, Fig. 1 ) and in tis sues from other sources. At the concentration of 0.1 m M 5-NiU inhibited dThdPase from uterine leiomyomas and uteri in 90,8% and 69%, respec tively. In mouse liver 5-NiU at the concentration of 0.4 m M inhibited dThdPase by 50% (Granharov et al., 1991) . The results of the inhibition study for 5-NiU in H eLa cells, mouse liver and human leu kocytes appeared to be similar in case of both dThd in our study and FU dR as substrates for this enzyme (W oodman et al., 1980) . The next position, in inhibitory potency is taken by 4,6DHNiP which inhibits dThdPase activity more effectively in leiomyomas -70% inhibition, at the inhibitor concentration of 0.1 mM (Table I) , than in mouse liver -less than 10% inhibition at the maximal inhibitor concentration of 2 m M (G ranharov et al., 1991) .
A less inhibitory potency is exhibited by 6-BTU, as showed in Table I (mixed inhibition, K x = 75.5 jiM for the leiomyomas). Interesting to note, that neither of the single-substituted compounds, 1.e. 2-thiouracil or 6-benzyluracil binds signifi cantly to mammalian dThdPase, whereas the com bination of these substitutions results in a 5-fold enhancem ent in binding relative to uracil (Niedzwicki et al., 1983) . Iltzch and Klein (1993) have reported that T.gondi UrdPase is similar to both mammalian U rdPase and dThdPase with respect to binding of uracil analogues substituted at the 5-position with electron-withdrawing groups. Substitutions at these types of groups for the C-5 hydrogen binding to all these enzymes, although the increase in bind ing to mammalian UrdPase and dThdPase is much greater than it is for T.gondi UrdPase. For exam ple, a bromo-group at the 5-position (5-BrU) in creases binding to mammalian dThdPase and U rd Pase 28-and 21-fold, respectively, but increases binding to T.gondi UrdPase only about 2-fold. These enzymes are also similar with respect to substitutions at the 6-position (Iltzch et al., 1993) . Substitution at C-5 position with electron-with drawing groups enhances binding significantly: brom o-28-fold, chloro-26-fold, iodo-17-fold, nitro-13-fold, fluoro-2-fold for mammalian dThdPase (Niedzwicki et al., 1983) . The studied compounds may be arranged in the following se- quence, depending on the potency of the inhibi tory effect: 5-BrU >5-NiU >5-FU >U. The last m entioned compound at the concentration of 0.1 m M exhibited only a 24% inhibition for dThdPase activity from uterine leiomyomas and no inhibition for uteri. The inhibition of these compounds is competitive (Dixon plot, Fig. 2) .
Literature data showed that 6-aminothymine is a potent inhibitor for dThdPase activity (Langen et al., 1967;  Niedzwicki et al., 1981) . 6-AU, on the other hand, inhibited less the activity of the dThdPase cleaving FU dR to various degrees de pending on the source of the enzyme . In comparison with previously m en tioned inhibitors in our study 6-AU appeared to be less effective 88 |im for uterine leiomyomas and ATj=130 lim for adjacent uterine tissue) ( Table I) .
The observed stronger inhibitory influence of these compounds on the activity of dThdPase from the studied leiomyomas may result from a better D EA E-Sepharose purification, greater sensitivity of dThdPase to tem perature, shorter half-life, or greater specific activity of the enzyme in compari
